IP Library Granted Patent US 11,207,273
Granted Patent B2
US 11,207,273 · App. 16/448,284 · Granted Dec 28, 2021

Method of making an L-menthol dosage form

Inventors: Syed M. Shah (Boca Raton, FL); Fred Hassan (Boca Raton, FL)
Assignee: Société des Produits Nestlé S.A.
A61K9/5057A61K9/0053A61K9/2054A61K9/2081A61K9/2095A61K9/4808A61K9/4833A61K9/4866A61K9/5026A61K9/5073A61K9/5089A61K31/045A61K36/23A61K36/534A61K36/82
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,207,273
App. No.
16/448,284
Granted
Dec 28, 2021
Kind
B2
Abstract

A method of making an L-menthol dosage form includes forming a wet granulation including an L-menthol source and at least one pharmaceutical excipient. The wet granulation is extruded into an extrudate and the extrudate is cut into individual core pieces. The individual core pieces are spheronized into individual spheronized cores and the individual spheronized cores are dried to form dried individual spheronized cores. The dried individual spheronized cores are spray coated with a liquid proteinaceous material that forms a film of a proteinaceous material over the dried individual spheronized cores. The film of proteinaceous material is dried over the dried individual spheronized cores to form individual subcoated cores. An enteric coating is applied and dried over the individual subcoated cores to form a plurality of individual enteric coated cores.

Claims (26)

1. A method of making an L-menthol dosage form, the method comprising:

forming a wet granulation including an L-menthol source and at least one pharmaceutical excipient;

extruding the wet granulation into an extrudate;

cutting the extrudate into individual core pieces;

spheronizing the individual core pieces into individual spheronized cores;

drying the individual spheronized cores to form dried individual spheronized cores;

spray coating the dried individual spheronized cores with a liquid proteinaceous material forming a film of proteinaceous material over the dried individual spheronized cores;

drying the film of proteinaceous material over the dried individual spheronized cores to form individual subcoated cores;

applying an enteric coating over the individual subcoated cores; and

drying the enteric coating over the individual subcoated cores to form a plurality of individual enteric coated cores;

wherein the dried film of proteinaceous material forms a barrier between the dried individual spheronized cores and enteric coating and wherein the dried film of proteinaceous material is effective to substantially prevent L-menthol from leaving the individual enteric coated cores when stored at 40 degrees C. and 75% relative humidity for 30 days.

2. The method of claim 1 , further comprising loading the plurality of individual enteric coated cores into a tablet, caplet, capsule, or sachet dosage form.

3. The method of claim 1 , wherein the individual enteric coated cores are spheroidal and have a diameter of 0.1 mm to 3 mm.

4. The method of claim 1 , wherein the L-menthol source is prepared by dissolving L-menthol in an essential oil.

5. The method of claim 1 , wherein the L-menthol source is peppermint oil.

6. The method of claim 1 , wherein the liquid proteinaceous material includes an aqueous gelatin solution.

7. The method of claim 1 , wherein the liquid proteinaceous material includes a 5% to 35% gelatin aqueous solution.

8. The method of claim 1 , wherein the liquid proteinaceous material includes acid bone gelatin.

9. The method of claim 1 , wherein the enteric coating includes a methacrylic acid based material.

10. The method of claim 1 , wherein the at least one pharmaceutical excipient includes both of methylcellulose and microcrystalline cellulose.

11. The method of claim 1 , wherein:

the L-menthol source is peppermint oil;

the at least one pharmaceutical excipient includes both of methylcellulose and microcrystalline cellulose; and

the liquid proteinaceous material includes acid bone gelatin.

12. The method of claim 1 , wherein drying the enteric coating includes heating from 20 degrees C. to 50 degrees C. without substantially losing L-menthol.

13. The method of claim 1 , wherein the film of proteinaceous material is a continuous gelatin film.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2020
From: ZX PHARMA, LLC
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054516/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2019
From: SHAH, SYED M.; HASSAN, FRED
To: ZX PHARMA, LLC
Reel/Frame 049550/0949 →
Continuity (6)
Continuation 14876465 · Oct 6, 2015
Continuation 14524326 · Oct 27, 2014
Continuation 14033713 · Sep 23, 2013
Provisional Application 61880294 · Sep 20, 2013
Provisional Application 61815073 · Apr 23, 2013
Related Publication 20190307701A1 · Oct 10, 2019